{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,22]],"date-time":"2026-02-22T21:28:13Z","timestamp":1771795693796,"version":"3.50.1"},"reference-count":51,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,5,22]],"date-time":"2021-05-22T00:00:00Z","timestamp":1621641600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Acta Pharmaceutica Sinica B"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1016\/j.apsb.2021.05.019","type":"journal-article","created":{"date-parts":[[2021,5,26]],"date-time":"2021-05-26T12:31:35Z","timestamp":1622032295000},"page":"774-786","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"title":["A novel PI3K inhibitor XH30 suppresses orthotopic glioblastoma and brain metastasis in mice models"],"prefix":"10.1016","volume":"12","author":[{"given":"Ming","family":"Ji","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dongjie","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Songwen","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chunyang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ling","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhihui","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Jin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deyu","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi","family":"Dong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heng","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Duo","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoguang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.apsb.2021.05.019_bib1","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1056\/NEJM200101113440207","article-title":"Brain tumors","volume":"344","author":"DeAngelis","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.apsb.2021.05.019_bib2","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/j.apsb.2019.01.006","article-title":"Menthol-modified casein nanoparticles loading 10-hydroxycamptothecin for glioma targeting therapy","volume":"9","author":"Gao","year":"2019","journal-title":"Acta Pharm Sin B"},{"key":"10.1016\/j.apsb.2021.05.019_bib3","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1016\/0360-3016(79)90554-6","article-title":"High dose radiation therapy in the treatment of malignant gliomas: final report","volume":"5","author":"Salazar","year":"1979","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.apsb.2021.05.019_bib4","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/s41572-018-0055-y","article-title":"Brain metastases","volume":"5","author":"Achrol","year":"2019","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.apsb.2021.05.019_bib5","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1007\/s11940-008-0033-x","article-title":"Brain metastases","volume":"10","author":"Eichler","year":"2008","journal-title":"Curr Treat Options Neurol"},{"key":"10.1016\/j.apsb.2021.05.019_bib6","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1016\/B978-0-7020-4088-7.00077-8","article-title":"Brain metastases","volume":"121","author":"Gallego Perez-Larraya","year":"2014","journal-title":"Handb Clin Neurol"},{"key":"10.1016\/j.apsb.2021.05.019_bib7","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.semcancer.2019.10.010","article-title":"Brain malignancies: glioblastoma and brain metastases","volume":"60","author":"Lah","year":"2020","journal-title":"Semin Canc Biol"},{"key":"10.1016\/j.apsb.2021.05.019_bib8","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/j.clon.2020.02.007","article-title":"Treating brain metastases from breast cancer: outcomes after stereotactic radiosurgery","volume":"32","author":"Wilson","year":"2020","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"10.1016\/j.apsb.2021.05.019_bib9","article-title":"Characterizing benefit from temozolomide in MGMT promoter unmethylated and methylated glioblastoma: a systematic review and meta-analysis","volume":"2","author":"Alnahhas","year":"2020","journal-title":"Neurooncol Adv"},{"key":"10.1016\/j.apsb.2021.05.019_bib10","article-title":"Medical management of brain metastases","volume":"2","author":"Lauko","year":"2020","journal-title":"Neurooncol Adv"},{"key":"10.1016\/j.apsb.2021.05.019_bib11","first-page":"2725","article-title":"Multifaceted resistance of gliomas to temozolomide","volume":"8","author":"Bocangel","year":"2002","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.apsb.2021.05.019_bib12","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20215347","article-title":"PD-L1\/PD-1 axis in glioblastoma multiforme","volume":"20","author":"Litak","year":"2019","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.apsb.2021.05.019_bib13","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1186\/s13046-019-1085-3","article-title":"Challenges and potential of PD-1\/PD-L1 checkpoint blockade immunotherapy for glioblastoma","volume":"38","author":"Wang","year":"2019","journal-title":"J Exp Clin Cancer Res"},{"key":"10.1016\/j.apsb.2021.05.019_bib14","doi-asserted-by":"crossref","first-page":"5287","DOI":"10.1158\/1078-0432.CCR-20-1135","article-title":"PD-1 Inhibitors: do they have a future in the treatment of glioblastoma?.","volume":"26","author":"Khasraw","year":"2020","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.apsb.2021.05.019_bib15","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1080\/21645515.2020.1782692","article-title":"PD-1\/PD-L1 immune checkpoint inhibitors in glioblastoma: clinical studies, challenges and potential","volume":"17","author":"Yang","year":"2021","journal-title":"Hum Vaccines Immunother"},{"key":"10.1016\/j.apsb.2021.05.019_bib16","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.ctrv.2003.07.007","article-title":"PI3K\/Akt signalling pathway and cancer","volume":"30","author":"Fresno Vara","year":"2004","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.apsb.2021.05.019_bib17","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.cell.2012.03.017","article-title":"mTOR signaling in growth control and disease","volume":"149","author":"Laplante","year":"2012","journal-title":"Cell"},{"key":"10.1016\/j.apsb.2021.05.019_bib18","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.cell.2006.01.016","article-title":"TOR signaling in growth and metabolism","volume":"124","author":"Wullschleger","year":"2006","journal-title":"Cell"},{"key":"10.1016\/j.apsb.2021.05.019_bib19","doi-asserted-by":"crossref","first-page":"100657","DOI":"10.1016\/j.jbior.2019.100657","article-title":"Class I phosphoinositide 3-kinase (PI3K) regulatory subunits and their roles in signaling and disease","volume":"75","author":"Rathinaswamy","year":"2020","journal-title":"Adv Biol Regul"},{"key":"10.1016\/j.apsb.2021.05.019_bib20","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1093\/neuonc\/noq193","article-title":"Inhibition of PI3K\/mTOR pathways in glioblastoma and implications for combination therapy with temozolomide","volume":"13","author":"Prasad","year":"2011","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.apsb.2021.05.019_bib21","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1007\/s13277-013-0800-5","article-title":"Targeting the PI3K\/AKT\/mTOR signaling pathway in glioblastoma: novel therapeutic agents and advances in understanding","volume":"34","author":"Sami","year":"2013","journal-title":"Tumour Biol"},{"key":"10.1016\/j.apsb.2021.05.019_bib22","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1038\/nrc1819","article-title":"Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis","volume":"6","author":"Cully","year":"2006","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.apsb.2021.05.019_bib23","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/j.ccr.2005.05.014","article-title":"Mutant PIK3CA promotes cell growth and invasion of human cancer cells","volume":"7","author":"Samuels","year":"2005","journal-title":"Cancer Cell"},{"key":"10.1016\/j.apsb.2021.05.019_bib24","doi-asserted-by":"crossref","first-page":"33440","DOI":"10.18632\/oncotarget.7961","article-title":"PI3K\/Akt\/mTOR signaling pathway and targeted therapy for glioblastoma","volume":"7","author":"Li","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.apsb.2021.05.019_bib25","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1093\/annonc\/mdx289","article-title":"Phase II study of copanlisib, a PI3K inhibitor, in relapsed or refractory, indolent or aggressive lymphoma","volume":"28","author":"Dreyling","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.apsb.2021.05.019_bib26","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1038\/nrclinonc.2018.28","article-title":"Targeting the PI3K pathway in cancer: are we making headway?.","volume":"15","author":"Janku","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.apsb.2021.05.019_bib27","first-page":"768","article-title":"Alpelisib: a novel therapy for patients with PIK3CA-mutated metastatic breast cancer","volume":"11","author":"Wilhoit","year":"2020","journal-title":"J Adv Pract Oncol"},{"key":"10.1016\/j.apsb.2021.05.019_bib28","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1124\/dmd.116.071423","article-title":"Brain distribution and efficacy of the brain penetrant PI3K inhibitor GDC-0084 in orthotopic mouse models of human glioblastoma","volume":"44","author":"Salphati","year":"2016","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.apsb.2021.05.019_bib29","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1158\/1535-7163.MCT-08-0017","article-title":"Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase\/mammalian target of rapamycin inhibitor with potent in\u00a0vivo antitumor activity","volume":"7","author":"Maira","year":"2008","journal-title":"Mol Cancer Therapeut"},{"key":"10.1016\/j.apsb.2021.05.019_bib30","doi-asserted-by":"crossref","first-page":"2445","DOI":"10.1158\/1078-0432.CCR-13-2403","article-title":"Phase I safety, pharmacokinetic, and pharmacodynamic study of SAR245409 (XL765), a novel, orally administered PI3K\/mTOR inhibitor in patients with advanced solid tumors","volume":"20","author":"Papadopoulos","year":"2014","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.apsb.2021.05.019_bib31","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.bcp.2016.02.015","article-title":"Poly(ADP-ribose) polymerases inhibitor, Zj6413, as a potential therapeutic agent against breast cancer","volume":"107","author":"Zhou","year":"2016","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.apsb.2021.05.019_bib32","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1083\/jcb.66.1.188","article-title":"Rapid flow cytofluorometric analysis of mammalian cell cycle by propidium iodide staining","volume":"66","author":"Krishan","year":"1975","journal-title":"J Cell Biol"},{"key":"10.1016\/j.apsb.2021.05.019_bib33","first-page":"97","article-title":"Tumor cell invasion assays","volume":"294","author":"Shaw","year":"2005","journal-title":"Methods Mol Biol"},{"key":"10.1016\/j.apsb.2021.05.019_bib34","doi-asserted-by":"crossref","first-page":"6087","DOI":"10.1021\/acs.jmedchem.8b00416","article-title":"Discovery and optimization of 2-amino-4-methylquinazoline derivatives as highly potent phosphatidylinositol 3-kinase inhibitors for cancer treatment","volume":"61","author":"Lin","year":"2018","journal-title":"J Med Chem"},{"key":"10.1016\/j.apsb.2021.05.019_bib35","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1111\/jcmm.13938","article-title":"IL-17A promotes cell migration and invasion of glioblastoma cells via activation of PI3K\/AKT signalling pathway","volume":"23","author":"Zheng","year":"2019","journal-title":"J Cell Mol Med"},{"key":"10.1016\/j.apsb.2021.05.019_bib36","first-page":"476","article-title":"Th17 cells and IL-17 are increased in patients with brain metastases from the primary lung cancer","volume":"16","author":"He","year":"2013","journal-title":"Chin J Lung Cancer"},{"key":"10.1016\/j.apsb.2021.05.019_bib37","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1242\/jcs.114.8.1439","article-title":"Phosphoinositide 3-kinase signalling pathways","volume":"114","author":"Cantrell","year":"2001","journal-title":"J Cell Sci"},{"key":"10.1016\/j.apsb.2021.05.019_bib38","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.4161\/cc.3.10.1164","article-title":"Oncogenic mutations of PIK3CA in human cancers","volume":"3","author":"Samuels","year":"2004","journal-title":"Cell Cycle"},{"key":"10.1016\/j.apsb.2021.05.019_bib39","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/nrc3860","article-title":"PI3K in cancer: divergent roles of isoforms, modes of activation and therapeutic targeting","volume":"15","author":"Thorpe","year":"2015","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.apsb.2021.05.019_bib40","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1158\/1078-0432.CCR-14-2522","article-title":"FDA approval: idelalisib monotherapy for the treatment of patients with follicular lymphoma and small lymphocytic lymphoma","volume":"21","author":"Miller","year":"2015","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.apsb.2021.05.019_bib41","doi-asserted-by":"crossref","first-page":"1820","DOI":"10.1158\/1078-0432.CCR-19-2808","article-title":"First-in-human phase I study to evaluate the brain-penetrant PI3K\/mTOR inhibitor GDC-0084 in patients with progressive or recurrent high-grade glioma","volume":"26","author":"Wen","year":"2020","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.apsb.2021.05.019_bib42","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1093\/neuonc\/nov083","article-title":"Phase I dose-escalation study of the PI3K\/mTOR inhibitor voxtalisib (SAR245409, XL765) plus temozolomide with or without radiotherapy in patients with high-grade glioma","volume":"17","author":"Wen","year":"2015","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.apsb.2021.05.019_bib43","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s11060-019-03227-7","article-title":"Phase I\/II study of bevacizumab with BKM120, an oral PI3K inhibitor, in patients with refractory solid tumors (phase I) and relapsed\/refractory glioblastoma (phase II)","volume":"144","author":"Hainsworth","year":"2019","journal-title":"J Neuro Oncol"},{"key":"10.1016\/j.apsb.2021.05.019_bib44","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.apsb.2016.07.006","article-title":"Class I phosphatidylinositol 3-kinase inhibitors for cancer therapy","volume":"7","author":"Zhao","year":"2017","journal-title":"Acta Pharm Sin B"},{"key":"10.1016\/j.apsb.2021.05.019_bib45","doi-asserted-by":"crossref","first-page":"C281","DOI":"10.1152\/ajpcell.00422.2003","article-title":"G1 cell cycle progression and the expression of G1 cyclins are regulated by PI3K\/AKT\/mTOR\/p70S6K1 signaling in human ovarian cancer cells","volume":"287","author":"Gao","year":"2004","journal-title":"Am J Physiol Cell Physiol"},{"key":"10.1016\/j.apsb.2021.05.019_bib46","doi-asserted-by":"crossref","first-page":"2708","DOI":"10.1529\/biophysj.105.077834","article-title":"The interplay of cell\u2013cell and cell\u2013matrix interactions in the invasive properties of brain tumors","volume":"91","author":"Hegedus","year":"2006","journal-title":"Biophys J"},{"key":"10.1016\/j.apsb.2021.05.019_bib47","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1007\/s10549-012-2389-6","article-title":"PI3K\/mTOR inhibition can impair tumor invasion and metastasis in\u00a0vivo despite a lack of antiproliferative action in\u00a0vitro: implications for targeted therapy","volume":"138","author":"Wander","year":"2013","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.apsb.2021.05.019_bib48","doi-asserted-by":"crossref","first-page":"30","DOI":"10.2174\/138920311795659407","article-title":"Role of mTOR signaling in tumor cell motility, invasion and metastasis","volume":"12","author":"Zhou","year":"2011","journal-title":"Curr Protein Pept Sci"},{"key":"10.1016\/j.apsb.2021.05.019_bib49","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1016\/j.immuni.2019.03.021","article-title":"The IL-17 family of cytokines in health and disease","volume":"50","author":"McGeachy","year":"2019","journal-title":"Immunity"},{"key":"10.1016\/j.apsb.2021.05.019_bib50","doi-asserted-by":"crossref","first-page":"108343","DOI":"10.1016\/j.clim.2020.108343","article-title":"The increased IL-17-producing gammadelta T cells promote tumor cell proliferation and migration in neuroblastoma","volume":"211","author":"Zhang","year":"2020","journal-title":"Clin Immunol"},{"key":"10.1016\/j.apsb.2021.05.019_bib51","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.canlet.2019.01.008","article-title":"IL-17 induces the proliferation and migration of glioma cells through the activation of PI3K\/Akt1\/NF-kappaB-p65","volume":"447","author":"Wang","year":"2019","journal-title":"Cancer Lett"}],"container-title":["Acta Pharmaceutica Sinica B"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211383521001854?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211383521001854?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T16:50:48Z","timestamp":1761929448000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211383521001854"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2]]},"references-count":51,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["S2211383521001854"],"URL":"https:\/\/doi.org\/10.1016\/j.apsb.2021.05.019","relation":{},"ISSN":["2211-3835"],"issn-type":[{"value":"2211-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2022,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A novel PI3K inhibitor XH30 suppresses orthotopic glioblastoma and brain metastasis in mice models","name":"articletitle","label":"Article Title"},{"value":"Acta Pharmaceutica Sinica B","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.apsb.2021.05.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences. Production and hosting by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}